Genervon Receives FDA Approval for Their Phase II Trial in ALS

Genervon Biopharmaceuticals discovered GM6 over ten years ago when they were working to identify a “master regulator” of multiple cellular pathways that could “correct defects in the nervous system”. GM6 (also called GM604) is a short peptide derived from motoneuronotrophic factor (MNTF), a protein involved in embryonic development. GM6 regulates over 4,000 different genes, including modulating over 80 ALS-related genes. This past December, Genervon announced that GM604 extends the life of SOD1 mice by 30%, and can delay the onset of ALS symptoms in these mice by 27%. Now, Genervon reports more exciting news; they recently received FDA approval for testing GM604 in a Phase IIa clinical trial in ALS. Genervon will soon be recruiting 12 patients for its broadly inclusive Phase IIa trial at two different locations: Massachusetts General Hospital and Columbia Medical Center in New York. Genervon also recently received approval for a Phase II study of GM6 in Parkinson’s disease, and they are currently recruiting patients for their Phase II study in Ischemic Stroke.

Genervon Biopharmaceuticals discovered GM6 over ten years ago when they were working to identify a “master regulator” of multiple cellular pathways that could “correct defects in the nervous system”. GM6 (also called GM604) is a short peptide derived from motoneuronotrophic factor (MNTF), a protein involved in embryonic development. GM6 regulates over 4,000 different genes, including modulating over 80 ALS-related genes. This past December, Genervon announced that GM604 extends the life of SOD1 mice by 30%, and can delay the onset of ALS symptoms in these mice by 27%. Now, Genervon reports more exciting news; they recently received FDA approval for testing GM604 in a Phase IIa clinical trial in ALS. Genervon will soon be recruiting 12 patients for its broadly inclusive Phase IIa trial at two different locations: Massachusetts General Hospital and Columbia Medical Center in New York. Genervon also recently received approval for a Phase II study of GM6 in Parkinson’s disease, and they are currently recruiting patients for their Phase II study in Ischemic Stroke.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail